01041nas a2200277   4500000000100000008004100001260001200042653001900054653001500073653002000088653001300108653001200121653001400133653002100147653004000168100001300208700001200221700001300233700001200246245005400258856006000312300001200372490000700384520035800391022001400749       2022                            d  c03/202210aHansen disease10atratamento10aQcrB inhibitors10aBacteria10aleprosy10atelacebec10aterminal oxidase10aTuberculosis and other mycobacteria1 aLahiri R1 aAdams L1 aThomas S1 aPethe K00aSensitivity of Mycobacterium leprae to Telacebec.  uhttps://wwwnc.cdc.gov/eid/article/28/3/pdfs/21-0394.pdf  a749-7510 v283 a<p>The treatment of leprosy is long and complex, benefiting from the development of sterilizing, rapidly-acting drugs. Reductive evolution made Mycobacterium leprae exquisitely sensitive to Telacebec, a phase 2 drug candidate for tuberculosis The unprecedented potency of Telacebec against M. leprae warrants further validation in clinical trials.</p>
  a1080-6059